EGFR and pancreatic ductal adenocarcinoma: EGFR overexpression was identified in the majority (87.4%) of AAC patients, which represents a higher proportion compared to the approximately 25–75% observed in colorectal cancers and about 45% in pancreatic ductal adenocarcinoma [27,28].